These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34366267)

  • 1. Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab.
    Freyer CW; Bange EM; Skuli S; Hsu M; Lin J; Cuker A; Cohen AD; Garfall A
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e845-e849. PubMed ID: 34366267
    [No Abstract]   [Full Text] [Related]  

  • 2. Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib.
    Moliz C; Gutiérrez E; Cavero T; Redondo B; Praga M
    Nefrologia (Engl Ed); 2019; 39(1):86-88. PubMed ID: 29716757
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab.
    Vakiti A; Singh D; Pilla R; Alhaj-Moustafa M; Fitzpatrick KW
    J Oncol Pharm Pract; 2019 Jun; 25(4):1011-1015. PubMed ID: 29768958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous
    Portuguese AJ; Lipe B
    Blood Adv; 2018 Dec; 2(23):3443-3446. PubMed ID: 30518536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postpartum atypical hemolytic uremic syndrome with complement factor H mutation complicated by reversible cerebrovascular constriction syndrome successfully treated with eculizumab.
    Yamaguchi M; Hori M; Hiroshi N; Maruyama S
    Thromb Res; 2017 Mar; 151():79-81. PubMed ID: 28167400
    [No Abstract]   [Full Text] [Related]  

  • 6. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
    Dedhia P; Govil A; Mogilishetty G; Alloway RR; Woodle ES; Abu Jawdeh BG
    Transplant Proc; 2017; 49(1):188-192. PubMed ID: 28104134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copy number variation analysis using next-generation sequencing identifies the
    Park J; Yhim HY; Kang KP; Bae TW; Cho YG
    Hematology; 2022 Dec; 27(1):603-608. PubMed ID: 35617302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Carfilzomib-induced haemolytic and uremic syndrome: Favorable outcome with eculizumab].
    Casiez C; Pica GM; Bally S
    Nephrol Ther; 2020 Jul; 16(4):221-224. PubMed ID: 32571738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
    Vondrák K; Seeman T
    Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy.
    Hisano M; Ashida A; Nakano E; Suehiro M; Yoshida Y; Matsumoto M; Miyata T; Fujimura Y; Hattori M
    Pediatr Int; 2015 Apr; 57(2):313-7. PubMed ID: 25868950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATYPICAL HEMOLYTIC UREMIC SYNDROME IN AN ADULT SUCCESSFULLY TREATED WITH ECULIZUMAB.
    Chaudoir C; Ong MG; Gu X; Veillon D; Cotelingam J
    J La State Med Soc; 2016; 168(1):12-5. PubMed ID: 26986861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical hemolytic-uremic syndrome.
    Kaartinen K; Martola L; Meri S
    Duodecim; 2017; 133(6):539-47. PubMed ID: 29243465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
    Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
    CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report.
    Sevinc M; Basturk T; Sahutoglu T; Sakaci T; Koc Y; Ahbap E; Akgol C; Kara E; Brocklebank V; Goodship TH; Kavanagh D; Unsal A
    J Med Case Rep; 2015 Apr; 9():92. PubMed ID: 25925370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab.
    Chonat S; Chandrakasan S; Kalinyak KA; Ingala D; Gruppo R; Kalfa TA
    Br J Haematol; 2016 Nov; 175(4):744-747. PubMed ID: 27870017
    [No Abstract]   [Full Text] [Related]  

  • 16. Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab.
    Nakamura H; Anayama M; Makino M; Makino Y; Tamura K; Nagasawa M
    Nephron; 2018; 138(4):324-327. PubMed ID: 29241200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.
    de Holanda MI; Pôrto LC; Wagner T; Christiani LF; Palma LMP
    Clin Rheumatol; 2017 Dec; 36(12):2859-2867. PubMed ID: 28905254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic and Therapeutic Challenges in Atypical Hemolytic Uremic Syndrome: A Case Report].
    Reis S; Ramos D; Cordinhã C; Gomes C
    Acta Med Port; 2019 Oct; 32(10):673-675. PubMed ID: 31625881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient.
    Bouwmeester RN; Ter Avest M; Wijnsma KL; Duineveld C; Ter Heine R; Volokhina EB; Van Den Heuvel LPWJ; Wetzels JFM; van de Kar NCAJ
    Front Immunol; 2020; 11():612706. PubMed ID: 33519821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies.
    Olson SR; Lu E; Sulpizio E; Shatzel JJ; Rueda JF; DeLoughery TG
    Am J Nephrol; 2018; 48(2):96-107. PubMed ID: 30110670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.